Holen Sie sich die Stockscreener-App
0.00
100.00%
-17.11
Schlusskurs vom Vortag:
$17.11
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$541.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$6.74M
KGV:
0.00
EPS:
0.2142
Netto-Cashflow:
$-412.70K
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$18.16
Veraxa Biotech Ag Stock (VACH) Company Profile
Firmenname
Veraxa Biotech Ag
Sektor
Branche
Telefon
03477204333
Adresse
C/O WINSTON & STRAWN LLP, HOUSTON
Compare VACH vs LION, XXI, UMAC, CCXI, DMII
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VACH
Veraxa Biotech Ag
|
0.00 | 541.25M | 0 | 6.74M | -412.70K | 0.2142 |
LION
Lionsgate Studios Corp
|
11.15 | 3.29B | 2.63B | -175.60M | 11.40M | -0.7173 |
XXI
Twenty One Capital Inc
|
5.45 | 3.17B | 0 | 4.35M | 456.40K | 0.3397 |
UMAC
Unusual Machines Inc
|
23.53 | 1.21B | 17.25M | -5.64M | -40.16M | -0.3337 |
CCXI
Churchill Capital Corp Xi
|
12.81 | 735.24M | 0 | 0 | 0 | 0.0647 |
DMII
Drugs Made In America Acquisition Ii Corp
|
10.17 | 647.19M | 0 | 8.58M | -1.11M | 0.134 |
Veraxa Biotech Ag Aktie (VACH) Neueste Nachrichten
Veraxa Biotech (VRXA) Insider Trading Activity 2026 - MarketBeat
VERAXA Biotech Designates Raju Willener as CFO - Yahoo Finance
VERAXA Biotech (NASDAQ: VRXA) Appoints Raju Willener As Chief Financial Officer - menafn.com
Veraxa Biotech AG (NASDAQ: VRXA) Names Raju Willener as CFO Following De-SPAC Completion - Kalkine Media
symbol__ Stock Quote Price and Forecast - CNN
VERAXA Biotech (VRXA) Appoints Raju Willener as Chief Financial Officer - Yahoo Finance
VERAXA Biotech (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer - USA Today
Veraxa Biotech (VRXA) Stock Price, News & Analysis - Stock Titan
VRXA Rises As Veraxa Biotech AG Draws Trader Focus - timothysykes.com
Veraxa Biotech AG Company Profile & Introduction - Moomoo
VRXA Jumps As Traders Focus On Biotech Breakout Setup - timothysykes.com
VRXA Should I Buy - Intellectia AI
VERAXA Biotech Appoints Veteran Finance Executive Raju Willener as CFO to Drive Capital Strategy and Oncology Pipeline Growth - citybuzz -
Veraxa Biotech AG (VRXA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Veraxa Biotech names Raju Willener as chief financial officer By Investing.com - Investing.com Australia
Veraxa Biotech AG Announces Chief Financial Officer Changes - marketscreener.com
Veraxa Biotech stock rises after naming Raju Willener as CFO By Investing.com - Investing.com India
Veraxa Biotech stock rises after naming Raju Willener as CFO - Investing.com
Finance veteran behind CHF 30B portfolios joins Veraxa Biotech (VRXA) as CFO - Stock Titan
Veraxa Biotech names Raju Willener as chief financial officer - Investing.com
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer - 富途牛牛
Veraxa Biotech (VRXA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Insider Buys Additional CHF75k In Veraxa Biotech Stock - simplywall.st
Veraxa Biotech (VRXA) Stock Chart and Price History 2026 - MarketBeat
Veraxa Biotech (VRXA) director adds 50K shares in open-market buy - Stock Titan
Veraxa Biotech (VRXA) CEO now holds 5,000 ordinary shares - Stock Titan
VERAXA Biotech (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation T - Benzinga
Early lab data advance Veraxa (Nasdaq: VRXA) autoimmune AOC - stocktitan.net
Veraxa and Secarna report positive early results from AOC study By Investing.com - Investing.com India
Veraxa Biotech AG - via.ritzau.dk
VERAXA Biotech Advances VXA-222 Cancer Program Beyond Discovery Phase, Strengthens IP Portfolio - citybuzz -
VERAXA Biotech AG: Valuation Ratios, Analysts' Forecasts - marketscreener.com
Veraxa Biotech (VRXA) interim CFO discloses zero share ownership - Stock Titan
VERAXA Biotech Leverages AI to Advance Precision Oncology Pipeline - citybuzz -
VERAXA Biotech Leverages AI to Enhance Precision Oncology Pipeline - citybuzz -
Dividend HistoryVeraxa Biotech AG (VRXA) - Zacks Investment Research
VRXA: Veraxa Biotech AGInsider Transations - Zacks Investment Research
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - USA Today
Finanzdaten der Veraxa Biotech Ag-Aktie (VACH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.26%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):